Targeting neuro-immune systems to achieve cardiac tissue repair following myocardial infarction: A review of therapeutic approaches from in-vivo preclinical to clinical studies

Smith, Sarah; Ascione, Raimondo

doi:10.1016/j.pharmthera.2023.108397

Cited by 3 publications

(1 citation statement)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…128 Bone marrow-derived mononuclear cells have been widely used in preclinical and clinical studies for MI treatment due to their accessibility and ease of procurement. 129–131 The therapeutic effect of BM-MNCs infusion in patients with MI or heart failure has been shown in clinical trials to be significantly influenced by trial design diversity and the inherent heterogeneity of BM-MNCs. 132 Overall, BM-MNCs are beneficial in the treatment of MI.…”

Section: Cell or Cell Derivative-laden Hydrogels For MI Therapymentioning

confidence: 99%

Cell or cell derivative-laden hydrogels for myocardial infarction therapy: from the perspective of cell types

Xiong,

An,

Chen

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Cell or Cell Derivative-laden Hydrogels For MI Therapymentioning

confidence: 99%

Cell or cell derivative-laden hydrogels for myocardial infarction therapy: from the perspective of cell types

Xiong,

An,

Chen

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Magnetostriction enhanced self-powered nanofiber sheet as cardiac patch with magnetoelectric synergistic effect on actuating Na+ k+-ATPase

Jing,

Tao,

et al. 2024

Chemical Engineering Journal

View full text Add to dashboard Cite

Intramyocardial immunomodulation with human CD16+ monocytes to treat myocardial infarction in pig: a blind randomized preclinical trial

Ascione,

Bruno,

Johnson

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundHuman CD16+ monocytes (hCD16+ Ms) have proangiogenic properties. We assessed the feasibility, safety and efficacy of hCD16+ Ms in a porcine model of myocardial infarction (MI).Methods and resultsA total of 27 female Large White pigs underwent MI with reperfusion and cardiac magnetic resonance (CMR). Five days later, animals received intramyocardial injections of hCD16+ Ms in saline (n = 13) or saline only (n = 14). hCD16+ Ms were selected from leucocyte cones. Feasibility/safety endpoints included injury at injected sites, malignant arrhythmias, cancer, haematoma, left ventricular (LV) dilatation, troponin release and downstream organ injury. Co-primary efficacy outcome included LV scar and ejection fraction (LVEF) at 30-day post-injections by CMR. Immunohistochemistry included neo-angiogenesis, fibrosis, markers of myofibroblast and inflammation. Four animals were excluded before injections due to untreatable malignant arrhythmias or lung injury. Median cell number and viability were 48.75 million and 87%, respectively. No feasibility/safety concerns were associated with the use of hCD16+ Ms. The LV scar dropped by 14.5gr (from 25.45 ± 8.24 to 10.8 ± 3.4 gr; −55%) and 6.4gr (from 18.83 ± 5.06 to 12.4 ± 3.9gr; −30%) in the hCD16+ Ms and control groups, respectively (p = 0.015). The 30-day LVEF did not differ between groups, but a prespecified sub-analysis within the hCD16+ Ms group showed that LVEF was 2.8% higher and LV scar 1.9gr lower in the subgroup receiving a higher cell dose. Higher tissue levels of neo-angiogenesis, myofibroblast and IL-6 and lower levels of TGF-β were observed in the hCD16+ Ms group.ConclusionsThe use of hCD16+ Ms in acute MI is feasible, safe and associated with reduced LV scar size, increased tissue levels of neo-angiogenesis, myofibroblasts and IL-6 and reduced pro-fibrotic TGF-β at 30-day post-injections. A higher cell dose might increase the LVEF effect while reducing scar size, but this warrants validation in future studies.

show abstract

Targeting neuro-immune systems to achieve cardiac tissue repair following myocardial infarction: A review of therapeutic approaches from in-vivo preclinical to clinical studies

Cited by 3 publications

References 142 publications

Cell or cell derivative-laden hydrogels for myocardial infarction therapy: from the perspective of cell types

Cell or cell derivative-laden hydrogels for myocardial infarction therapy: from the perspective of cell types

Magnetostriction enhanced self-powered nanofiber sheet as cardiac patch with magnetoelectric synergistic effect on actuating Na+ k+-ATPase

Intramyocardial immunomodulation with human CD16+ monocytes to treat myocardial infarction in pig: a blind randomized preclinical trial

Contact Info

Product

Resources

About